Last reviewed · How we verify
Alprolix
Alprolix is a Small molecule drug developed by Swedish Orphan Biovitrum. It is currently FDA-approved for Hereditary factor IX deficiency disease. Also known as: Eftrenonacog alfa, rFIXFc, Eftrenonacog alfa, rFIXFc.
Alprolix is a protein-based medication used to treat Hemophilia A and Hemophilia B, and it works by replacing the deficient coagulation factor IX. It is classified as an exogenous protein and is administered to patients with congenital bleeding disorders, including those with excessive menstrual flow.
At a glance
| Generic name | Alprolix |
|---|---|
| Also known as | Eftrenonacog alfa, rFIXFc, Eftrenonacog alfa, rFIXFc |
| Sponsor | Swedish Orphan Biovitrum |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Hereditary factor IX deficiency disease
Common side effects
- Headache
- Oral paresthesia
- Obstructive uropathy
- Injection site erythema
- Hypersensitivity
Serious adverse events
- Factor IX inhibition
Key clinical trials
- An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B
- A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
- A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France
- Study of Surgical Practices in Patients With Haemophilia A or B Treated With an Extended Half-life Recombinant Factor VIII-Fc or IX-Fc (ELOCTA®, ALPROLIX®)
- A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B (PHASE1)
- Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B (PHASE3)
- ATHN 2: Factor Switching Study
- Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alprolix CI brief — competitive landscape report
- Alprolix updates RSS · CI watch RSS
- Swedish Orphan Biovitrum portfolio CI
Frequently asked questions about Alprolix
What is Alprolix?
What is Alprolix used for?
Who makes Alprolix?
Is Alprolix also known as anything else?
What development phase is Alprolix in?
What are the side effects of Alprolix?
Related
- Manufacturer: Swedish Orphan Biovitrum — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Hereditary factor IX deficiency disease
- Also known as: Eftrenonacog alfa, rFIXFc, Eftrenonacog alfa, rFIXFc
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing